Search Results - peptides%2fprodrugs

7 Results

Sort By:

Combinations of ASOs for the Modulation of SMN Expression in SMA Patients

Unmet NeedSpinal muscular atrophy (SMA) is a devastating neuromuscular disease that predominantly affects children and is the most common cause of hereditary infant mortality. The disease is caused by low levels of survival motor neuron (SMN) protein, due to recessive mutations in the SMN1 gene. Importantly, the copy number variation of SMN2, a homologous...

Published: 3/13/2026 | Inventor(s): Charlotte Sumner, Constantin d'Ydewalle, Frank Rigo, C. Bennett

Keywords(s): CNS and Neurological Disorders, Combination, Disease Indication, Drug Delivery Vehicle, Muscle Atrophy, Muscular Disorders, Neurodegenerative Diseases, Peptides/Prodrugs, Single, Targeted Therapy, Therapeutic Matter, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations > Neurology > Motor Neuron Diseases, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities > Proteins

A peptide that forms pores in membranes at acidic pH for the delivery of macromolecules through the plasma membrane or endosomes, or the lysis of cancer cells.

Unmet Need There are significant roadblocks to the routine delivery of macromolecules such as proteins, peptides, imaging agents, polysaccharides and more to the cytosol of mammalian cells. While most macromolecules are easily directed to existing cellular uptake mechanisms, they are often trapped in endosomal pathways leading to lysosomal degradation...

Published: 3/12/2026 | Inventor(s): Kalina Hristova, Gregory Wiedman, William Wimley, Sarah Kim

Keywords(s): Biologics, Drug Delivery Vehicle, Peptide, Peptides/Prodrugs, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Peptides, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities

Human Serum Albumin-PSA proaerolysin Prodrug

UNMET NEEDThe current standards of care for prostate cancer (Pca) include hormonal therapy, radiation therapy, surgery, chemotherapy, and combinational therapy. However, these treatments often have side effects that affect the quality of life of the Pca patients. Hence, there is an urgent need for developing better target-based therapies. This technology...

Published: 3/12/2026 | Inventor(s): John Isaacs, Samuel Denmeade, William Brennen

Keywords(s): Biologics, Cancers, Disease Indication, Drug Delivery Vehicle, Peptides/Prodrugs, Prostate Cancer, Protein, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Men's Health, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Proteins, Technology Classifications > Therapeutic Modalities > Peptides, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Prostate Cancer

Self-assembling CPT-drug Amphiphiles for Cancer Treatment

Unmet need: DNA topoisomerases have become a widely exploited chemotherapeutic drug target for the treatment of advanced cancer. Multiple classes of topoisomerase inhibitors have been marketed including camptothecin (CPT) derivatives. However, while these analogues are less toxic than CPT, they are have reduced efficacy due to their prodrug formulation,...

Published: 3/13/2026 | Inventor(s): Honggang Cui, Hao Su, Feihu Wang

Keywords(s): Cancers, Disease Indication, Drug Delivery Vehicle, Peptides/Prodrugs, Therapeutic Matter, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology

Supramolecular Hydrogel Applications to the Carotid Bodies to Treat Hypertension and Sleep Apnea in Obesity

Unmet NeedOver one-third of adults in the U.S. (36.5%) have obesity. Further, obesity leads to increased cardiovascular morbidity and mortality via multiple adverse mechanisms that include increased prevalence and severity of hypertension (often resistant to treatment) and obstructive sleep apnea (OSA). Currently, no pharmacotherapy exists for OSA....

Published: 3/13/2026 | Inventor(s): Vsevolod Polotsky, Honggang Cui, Roxana Mitrut, Mi-kyung Shin

Keywords(s): Cardiovascular Diseases, CNS and Neurological Disorders, Disease Indication, Drug Delivery Vehicle, Hypertension, Metabolic Disorders, Obesity, Peptides/Prodrugs, Sleep Apnea, Sleep Disorders, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Peptides, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Clinical and Disease Specializations > Cardiovascular > Hypertension, Clinical and Disease Specializations > Sleep Disorders > Sleep Apnea, Clinical and Disease Specializations > Obesity

Self-Assembling Drug-Amphiphiles: A New Platform for the Delivery of Anticancer Chemotherapeutics

UNMET NEEDMany anticancer drug delivery systems suffer from lack of target specificity and drug-loading limitations. Additionally, many drug delivery systems require the use of a nanocarrier, which have certain disadvantages including limitations on the amount of loaded drug and batch to batch variability. This invention is a self-assembled drug-amphiphile...

Published: 3/12/2026 | Inventor(s): Andrew Cheetham, Pengcheng Zhang, Honggang Cui

Keywords(s): Cancers, Chemotherapy, Disease Indication, Drug Delivery Vehicle, Peptides/Prodrugs, Single, Therapeutic Matter, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Peptides, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities

A Novel Sublingual Film for the Treatment of Peanut Allergy

C11103: A Novel Sublingual Film for the Treatment of AllergyValue Proposition: JHU inventors have developed a mucoadhesive film containing a quantity of allergen to be placed under the tongue for the purpose of reducing adverse reactions to allergens by immunotherapy. ADVANTAGES:- A mucoadhesive film held under the tongue for immunotherapy addresses...

Published: 3/12/2026 | Inventor(s): Russell Martin, Hai-Quan Mao, Robert Wood, Corinne Keet

Keywords(s): Allergies, Disease Indication, Drug Delivery Vehicle, Immunotherapy, Inflammatory Disorders, Peptides/Prodrugs, Single, Therapeutic Matter, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Inflammation > Allergies, Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Peptides, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Clinical and Disease Specializations > Inflammation